WorldCat Identities

Fabbri, Alberto

Overview
Works: 25 works in 43 publications in 3 languages and 550 library holdings
Genres: Pictorial works  History 
Roles: Author, Creator, Contributor, Other
Publication Timeline
.
Most widely held works by Alberto Fabbri
Unione europea e fenomeno religioso by Alberto Fabbri( )

3 editions published in 2012 in Italian and held by 454 WorldCat member libraries worldwide

Effetti giuridici delle annessioni territoriali, con speciale reguardo alle annession di Fiume e della Dalmazia nei rapporti italo-jugoslavi by Alberto Fabbri( Book )

7 editions published in 1931 in Italian and held by 21 WorldCat member libraries worldwide

SPAZIO PUBBLICO PER IL FENOMENO RELIGIOSOE-BOOK by Vittorio Parlato( )

1 edition published in 2020 in Italian and held by 15 WorldCat member libraries worldwide

Unione europea e fenomeno religioso : alcune valutazioni di principio by Alberto Fabbri( Book )

3 editions published in 2012 in Italian and held by 10 WorldCat member libraries worldwide

Bagni di Chianciano : dalla fine dell'800 al 1925 la trasformazione di una comunità fra cronaca e storia by Alberto Fabbri( Book )

4 editions published in 2000 in Italian and held by 8 WorldCat member libraries worldwide

Chianciano fegato sano : 1926-1952 gli anni dello sviluppo e dell'affermazione della stazione termale by Alberto Fabbri( Book )

3 editions published in 2003 in Italian and held by 8 WorldCat member libraries worldwide

Geheime Beweiserhebung in der Schweiz im Rahmen der internationalen Strafrechtskooperation by Alberto Fabbri( )

2 editions published in 2013 in German and held by 6 WorldCat member libraries worldwide

Polizeiliche Ermittlung oder staatsanwaltliche Untersuchung? : Abgrenzungen im Vorverfahren nach schweizerischer Strafprozessordnung by Alberto Fabbri( )

1 edition published in 2014 in German and held by 4 WorldCat member libraries worldwide

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice by Elisabeth Schorb( )

1 edition published in 2020 in English and held by 3 WorldCat member libraries worldwide

Abstract: The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). However, nothing is known about its feasibility and efficacy in everyday practice, where patients are more often older/frailer than those enrolled in clinical trials. We conducted a retrospective study addressing tolerability/efficacy of MATRix in 156 consecutive patients with newly diagnosed PCNSL treated outside a clinical trial. Median age and ECOG Performance Status of considered patients were 62 years (range 28-78) and 2 (range 0-4). The overall response rate after MATRix was 79%. Nine (6%) treatment-related deaths were recorded. After a median follow-up of 27.4 months (95% confidence interval [CI] 24.4-31.9%), the two-year progression-free and overall survival were 56% (95% CI 48.4-64.9%) and 64.1% (95% CI 56.7-72.5%) respectively. Patients not eligible for the IELSG32 trial were treated with lower dose intensity and had substantially worse outcomes than those fulfilling inclusion criteria. This is the largest series of PCNSL patients treated with MATRix outside a trial and recapitulates the IELSG32 trial outcomes in the non-trial setting for patients who fit the trial criteria. These data underscore the feasibility and efficacy of MATRix as induction treatment for fit patients in routine practice
Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature by Maria Raffaella Ambrosio( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Die Verfahrensbeschwerde gemäss [Par.] 120 StPO BL : aus der Praxis des Verfahrensgerichts in Strafsachen im Jahr 2000 by Christine von Arx( )

2 editions published in 2002 in German and held by 2 WorldCat member libraries worldwide

La confraternita della buona morte di Urbino tra storia e diritto by Alberto Fabbri( )

1 edition published in 2015 in Italian and held by 2 WorldCat member libraries worldwide

Coexistence of Serum Monoclonal Gammopathy of Uncertain Significance and Hodgkin Lymphoma by Emanuele Cencini( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Unione europea e fenomeno religioso : alcune valutazioni di principio by Alberto Fabbri( Book )

2 editions published in 2012 in Italian and held by 2 WorldCat member libraries worldwide

Capitolo IV - Gli effetti dell'adesione dell'unione Europea alla convenzione per la salvaguardia dei diritti dell'uomo e delle libertà fondamentali (CEDU) nella sfera della tutela della libertà religiosaCapitolo V - Le prospettive e le modalità di intervento delle due Corti sul fenomeno religioso; Indice degli autori; Ultimato di stampa
I disabili e l'avviamento al lavoro by Alberto Fabbri( Book )

1 edition published in 1999 in Italian and held by 1 WorldCat member library worldwide

Die Anwendbarkeit des Schweizerischen Strafrechts bei Völkerstrafrechtstaten : eine Bestandaufnahme by Alberto Fabbri( )

1 edition published in 2006 in German and held by 1 WorldCat member library worldwide

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Background: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy. Methods: HIV-negative patients (aged 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group performance status of 0-3 were randomly assigned to receive four courses of methotrexate 3·5 g/m 2 on day 1 plus cytarabine 2 g/m 2 twice daily on days 2 and 3 (group A); or the same combination plus two doses of rituximab 375 mg/m 2 on days −5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m 2 on day 4 (group C), with the three groups repeating treatment every 3 weeks. Patients with responsive or stable disease after induction treatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatrogenic side-effects, were eligible for the second randomisation between WBRT (photons of 4-10 MeV; five fractions per week; fraction size 180 cGy; started within 4 weeks from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m 2 on day −6, and thiotepa 5 mg/kg every 12 h on days −5 and −4, followed by reinfusion of autologous peripheral blood stem cells; group E). A permuted block randomised design was adopted for both randomisations, and a computer-generated randomisation list was used within each stratum. No masking after assignment to intervention was adopted. The primary endpoint was 2-year progression-free survival, with induction group and response to induction chemotherapy as stratification parameters. Analyses were done on a modified intention-to-treat basis. This study is registered withClinicalTrials.gov, numberNCT01011920 . Findings: Between Feb 19, 2010, and Aug 27, 2014, 227 patients were recruited from 53 centres in five countries. 219 of 227 enrolled patients were assessable. Of the 122 patients eligible for the second randomisation, 118 patients were randomly assigned to WBRT or ASCT (59 patients per group) and constitute the study population. WBRT and ASCT were both effective, and achieved the predetermined efficacy threshold of at least 40 progression-free survivors at 2 years among the first 52 patients in both groups D and E. There were no significant differences in 2-year progression-free survival between WBRT and ASCT: 80% (95% CI 70-90) in group D and 69% (59-79) in group E (hazard ratio 1·50, 95% CI 0·83-2·71; p=0·17). Both consolidation therapies were well tolerated. Grade 4 non-haematological toxicity was uncommon; as expected, haematological toxicity was more common in patients treated with ASCT than in those who received WBRT. Two toxic deaths (infections) were recorded, both in patients who received ASCT. Interpretation: WBRT and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma. The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision. Funding: Agenzia Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Science Foundation
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.27 (from 0.15 for Unione eur ... to 0.98 for Effetti gi ...)

Languages